Transatlantique Private Wealth LLC Invests $848,000 in Natera, Inc. (NASDAQ:NTRA)

Transatlantique Private Wealth LLC bought a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 5,354 shares of the medical research company's stock, valued at approximately $848,000.

Several other hedge funds have also recently added to or reduced their stakes in NTRA. Blue Trust Inc. increased its stake in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after buying an additional 166 shares during the period. EverSource Wealth Advisors LLC boosted its stake in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. raised its position in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after acquiring an additional 332 shares during the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 610 shares of the business's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $145.55, for a total transaction of $88,785.50. Following the completion of the transaction, the chief financial officer now owns 76,468 shares of the company's stock, valued at approximately $11,129,917.40. The trade was a 0.79 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 13,685 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total value of $2,269,930.95. Following the completion of the sale, the chief executive officer now directly owns 253,944 shares in the company, valued at $42,121,691.28. This trade represents a 5.11 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 199,194 shares of company stock valued at $30,646,524. Insiders own 7.60% of the company's stock.

Natera Stock Up 4.0 %

Shares of NTRA traded up $5.92 during mid-day trading on Thursday, hitting $154.48. 792,607 shares of the company's stock were exchanged, compared to its average volume of 1,377,938. The stock has a market cap of $20.88 billion, a price-to-earnings ratio of -87.77 and a beta of 1.80. The firm has a fifty day moving average of $148.64 and a two-hundred day moving average of $153.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $87.20 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. On average, sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. BTIG Research reissued a "buy" rating on shares of Natera in a research note on Friday, February 28th. Royal Bank of Canada started coverage on shares of Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price for the company. The Goldman Sachs Group raised their price objective on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Finally, Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Natera presently has a consensus rating of "Moderate Buy" and an average price target of $175.76.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.